Investigation of immunosuppressive mechanisms in a mouse glioma model

Journal of Neuro-Oncology

Volumn 93, Issue 1, 2009, Pages 107-114

  Ksendzovsky, Alexander ^a   Feinstein, Douglas ^b,c   Zengou, Ryan ^d   Sharp, Anthony ^b,c   Polak, Paul ^b,c   Lichtor, Terry ^d   Glick, Roberta P ^b,d,e  

^a The Chicago Medical College   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e MOUNT SINAI HOSPITAL   (United States)

Author keywords

Cytokine; Cytokine array; Glioma; Immunosuppression; Immunotherapy; TGF

Indexed keywords

ALPHA INTERFERON; CD3 ANTIBODY; CD3 ANTIGEN; CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; DECOY RECEPTOR 3; FAS ANTIGEN; GELATINASE A; GLUCOSE TRANSPORTER 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 22; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTRAXIN 3; SOMATOMEDIN BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DISEASE MODEL; DOWN REGULATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOMA; GLIOMA CELL; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ANIMALS; ANTIGENS, CD3; BRAIN NEOPLASMS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLIOMA; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 65649086824     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9884-6     Document Type: Article

References (35)

1. Taub DD, Lloyd AR, Conlon K et al (1992) Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177:1809-1814
2. Uhl M, Aulwurm S, Wischhusen J et al (2004) SD-208, A novel transforming growth factor B Receptor I Kinase Inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64:7954
3. Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531
4. Misra N, Bayry J, Lacroix-Desmazes S et al (2004) Cutting edge: Human CD4+ CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676
5. Taams LS, van Amelsfort JM, Tiemessen MM et al (2005) Modulation of monocyte/macrophage function by human CD4+ CD25+ regulatory T cells. Hum Immunol 66:222
6. Fecci PE, Ochiai H, Mitchell DA et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13:2158
7. Fecci PE, Sweeney AE, Grossi PM et al (2006) Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 12:4294
8. Lichtor T, Glick RP (2003) Cytokine immune-gene therapy for treatment of brain tumors. J Neuro-oncology 65:247-259
9. Lichtor T, Glick RP, Tarlock K, Moffet S, Mouw E, Cohen EP (2002) Application of interleukin-2 secreting syngenec/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Therapy 9:464-469
10. Grauer OM, Nierkens S, Bennink E, Toonen LWJ, Boon L, Wesseling P, Sutmuller R, Adema GJ (2007) CD4+ FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune response in vivo. Int J Cancer 121:95-105
11. Kaminska B, Wesolowska A, Danilkiewicz M (2005) TGF beta signaling and its role in tumour pathogenesis. Acta Bioch Pol 2:329-337
12. Wick W, Platten M, Weller M (2004) Glioma cell invasion: Regulation of metalloproteinase activity by TGF-beta. J Neuroonc 53:177-185
13. Benckert C, Jonas S, Cramer T, Von Marschall Z et al (2003) Transforming growth factor beta-1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63:1083-1092
14. Sugano Y, Matsuzaki K, Tahashi Y et al (2003) Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells. Oncogene 22:2309-2321
15. Fakhrai H, Dorigo O, Shawler DL et al (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93:2909
16. Platten M, Wild-Bode C, Wick W et al (2001) N-[3, 4-Dimethoxycinnamoyl]-Anthranilic acid (Tranilast) inhibits Transforming Growth Factor-B release and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer 93:53
17. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A et al (2006) Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev 17:129
18. Jordan JT, Sun W, Hussain F, DeAngulo G, Prabhu SS, Heimberger AB (2008) Preferential migration of regulatory T cells mediated by glioma-secreted cytokines can be blocked with chemotherapy. Can Immun Immuno 57:123-131
19. Zumkeller W, Westphal M (2001) The IGF/IGFBP system in CNS malignancy. J Clin Pathol 54:227-229
20. Glick RP, Gettleman R, Patel K, et al (1989) Insulin and insulin-like growth factor I in brain tumors: Binding and in vitro effects. Neurosurg 24:791-797
21. Glick RP, Unterman TG, Hollis R (1991) Radioimmunoassay of insulin-like growth factors in cyst fluid of central nervous system tumors. J Neurosurg 74:972-978
22. Glick RP, Unterman TG, Van der Woude M, Blaydes LZ (1992) Insulin and insulin-like growth factors in central nervous system tumors: Part V: production of insulin-like growth factors I and II in vitro. J Neurosurg 77:445-450
23. Kikuchi T, Joki T, Akasaki Y (1999) Induction of antitumor immunity using Intracellular Adhesion Molecule 1 (ICAM-1) transfection in mouse glioma cells. Cancer Lett 142:201-206
24. Chen TC, Hinton DR, Apuzzo ML et al (1993) Differential effects of tumor necrosis factor - alpha on proliferation, cell surface antigen expression, and cytokine interactions in malignant gliomas. Neurosurg 32:85-94
25. Kuppner MC, van Meir E, Hamou MF et al (1990) Cytokine regulation of intercellular adhesion molecule-1 expression on human glioblastoma cells. Exp Immunolog 81:142-148
26. Meager A (1996) Bio-immunoassay of pro-inflammatory cytokines involving cytokine induced cellular adhesion molecule expression in human glioblastoma cell lines. J Immunolog Methods 190:235-244
27. Liao F, Rabin R, Yannelli J et al (1995) Human mig chemokine: biochemical and functional characterization. J Exp Med 182:1301-1314
28. Loetscher M, Gerber B, Loetscher P et al (1996) Chemokine receptor specific for IP-10 and mig: Structure, function, and expression in activated T-lymphocytes. J Exp Med 184:963-969
29. Angiolillo AL, Sgadari C, Taub DD et al (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182:155-162
30. Strieter RM, Polverini PJ, Kunkel SL et al (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270:27348-27357
31. Kanegane C, Sgadari C, Kanegane, H et al 1998 Contribution of the CXC chemokines IP-10 and mig to the antitumor effects of IL-12. J Leukoc Biol 64: 384-392
32. Luster AD, Leder P (1993) IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumour response in vivo. J Exp Med 178:1057-1065
33. Pertl U, Luster AD, Varki et al (2001) IFN-γ -inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 166:6944-6951
34. Hiroi M, Ohmori Y (2003) Constitutive nuclear factor κB activity is required to elicit. Interferon-γ-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines. Biochem J 376:393-401
35. Mantovani A, Garlanda C, Bottazi B (2003) Pantraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 21:43-47